Artivion, Inc 8-K, filed May 25, 2021
Artivion, Inc. (AORT)
About this 8-K
Artivion, Inc filed this 8-K on May 25, 2021, reporting on events of May 19, 2021.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM
___________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
___________________________________________
(Exact name of registrant as specified in its charter)
___________________________________________
|
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (
_________________________________________________________
(Former name or former address, if changed since last report)
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
Section 5 | Corporate Governance and Management |
|
|
Item 5.07 | Submission of Matters to a Vote of Security Holders |
At CryoLife, Inc.’s (the “Company” or “CryoLife”) 2021 Annual Meeting of Stockholders held on May 19, 2021 (the “Annual Meeting”), CryoLife’s stockholders elected each individual that was nominated for election as director of the Company to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also (i) approved, by non-binding vote, the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, and (ii) ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2021.
The final results of the voting on each matter of business at the 2021 Annual Meeting are as follows:
Election of Directors
|
|
|
|
Name | Votes For | Votes Withheld | Broker Non-Votes |
Thomas F. Ackerman | 29,020,959 | 965,344 | 2,773,817 |
Daniel J. Bevevino | 28,840,886 | 1,145,417 | 2,773,817 |
Marna P. Borgstrom | 29,921,936 | 64,367 | 2,773,817 |
James W. Bullock | 29,029,735 | 956,568 | 2,773,817 |
Jeffrey H. Burbank | 28,107,926 | 1,878,377 | 2,773,817 |
J. Patrick Mackin | 29,570,916 | 415,387 | 2,773,817 |
Ronald D. McCall, Esq. | 27,774,336 | 2,211,967 | 2,773,817 |
Harvey Morgan | 29,339,020 | 647,283 | 2,773,817 |
Jon W. Salveson | 28,325,916 | 1,660,387 | 2,773,817 |
Approval, by non-binding vote of the compensation paid to CryoLife’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.
|
|
|
|
|
|
|
|
Votes For | Votes Against | Votes Abstain | Broker Non-Votes |
28,793,763 | 960,132 | 232,408 | 2,773,817 |
Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2021.
|
|
|
|
Votes For | Votes Against | Votes Abstain |
|
32,660,019 | 69,512 | 30,589 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 25, 2021
|
|
|
|
|
|
|
|
| CRYOLIFE, INC. | ||
|
|
|
|
| By: | /s/ D. Ashley Lee |
|
| Name: | D. Ashley Lee |
|
| Title: | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
|